Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer | OncLive

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

February 7, 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

With the advent of PARP inhibitors in prostate cancer, Morgan says that investigators are considering these agents in combination with already-established treatment modalities. PARP inhibitors are being looked at with androgen receptor-directed therapies, immunotherapy approaches, and radiation.

Additionally, there is interest in understanding whether there is a synergistic action with platinum agents. There is some evidence that patients who have DNA repair defects may be more sensitive to agents such as carboplatin compared to traditional chemotherapy with docetaxel.

Morgan says that the potential of adding other therapies to PARP inhibitors is exciting, and combinations will hopefully be a part of the future treatment landscape of prostate cancer.


x